Compare Enveric Biosciences Inc (ENVB) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Warner Music Group Corp — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Warner Music Group Corp trades at $28.87 (market cap $14.73B). The key difference: Warner Music Group Corp is far larger — about 2201.8× Enveric Biosciences Inc's market cap, and Warner Music Group Corp pays a 2.84% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Warner Music Group Corp for 96 Days on average.
| ENVB | WMG | |
|---|---|---|
Market Cap | $6.69M | $14.73B |
Volume | 41,141 | 2,404,416 |
Sector | Health | Media |
52-Week High | $10.80 | $34.72 |
52-Week Low | $1.27 | $23.65 |
Typical Hold Time | 14 Days | 96 Days |
Enterprise Value | -$1.60M | $19.03B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Warner Music Group (WMG) trades at $28.91, up 4.71% with strong technical momentum and bullish moving average signals. The company delivered Q2 2026 earnings beat with EPS of $0.38 versus $0.34 expected, continuing positive earnings momentum. Recent partnerships with AI music platforms and strategic licensing renewals highlight growth initiatives in the evolving music industry landscape.
WMG presents compelling value with analyst consensus target of $39.50 (36% upside) and strong institutional buying. However, elevated P/E of 22.52 and recent CFO departure pose execution risks. The stock's 92.72% ROE demonstrates exceptional capital efficiency, but investors should monitor AI integration execution and streaming revenue sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
